Peptide Research Glossary: The Terms Every Buyer Should Know

A peptide vial arrives with a label, a lot number, and sometimes a Certificate of Analysis, and a new researcher is expected to already know what all of it means. This glossary collects the vocabulary that keeps coming up around sourcing, reconstituting, testing and describing peptides for laboratory research, organized so you can jump to the cluster you actually need. Where a term maps to something concrete on this site, a product, a category, or a calculation tool, we link it directly. Every batch we sell ships with a per-batch third-party CoA from Janoshik or Liquilabs, browsable at /coa with the testing methodology summarized at /purity, so several entries below double as a short explainer of what that document is actually reporting.

Handling and Reconstitution

• Lyophilized (freeze-dried). Water is removed from a frozen solution by sublimation under vacuum, avoiding heat exposure and leaving a dry cake. It is the standard preservation format for peptides because water in solution speeds up degradation reactions like hydrolysis and oxidation.
• Reconstitution. Dissolving a lyophilized peptide back into a liquid, most often bacteriostatic water or sterile water for injection, before further handling or use in an assay.
• Bacteriostatic water (BAC water). Sterile water containing 0.9% (9 mg/mL) benzyl alcohol as a preservative. Benzyl alcohol inhibits bacterial growth without killing it outright, bacteriostatic rather than bactericidal, which is why a broached multi-dose vial is commonly used across a window of up to about 28 days instead of being treated as single-use.
• Sterile water for injection. Sterile water with no added preservative. Because nothing suppresses microbial growth once the seal is broken, it is generally treated as a single-entry solution rather than a multi-dose diluent.
• Acetic acid water. A dilute acetic acid solution used as a reconstitution diluent for peptides that dissolve or remain stable more reliably in a mildly acidic environment than in plain water.
• Aliquot / aliquoting. Dividing a reconstituted solution into smaller single-use portions right after mixing, so that only one portion is thawed and exposed to air per use rather than repeatedly re-entering and re-freezing one working vial.
• Freeze-thaw cycle. One full freeze-and-thaw of a solution. Repeated cycling is a recognized degradation risk for peptides, driven by ice-crystal formation and repeated air exposure at the solution surface, which is the practical argument for aliquoting before the first freeze rather than after.
• Cold-chain. The unbroken sequence of refrigerated or frozen storage and transport that keeps a temperature-sensitive material within its intended range from manufacture to bench. A broken segment, a warm layover in transit or a vial left out overnight, can degrade a peptide before it is ever used.
• Desiccant. A moisture-absorbing packet or capsule included with lyophilized product to keep residual humidity low in storage, since a peptide cake left in a humid environment reabsorbs water and loses some of the stability benefit lyophilization was meant to provide.
• Mannitol (bulking agent / excipient). The most common inert filler added to a peptide solution before lyophilization. It crystallizes on freezing to form a stable, low-residual-moisture cake and is chemically inert toward peptide side chains under normal storage, which is why a lyophilized vial often looks like more powder than the peptide mass alone would produce.
• Amber vial / light sensitivity. Some peptides are reported to degrade faster under light exposure, so vendors package or researchers store them in amber glass or foil-wrapped containers to limit that exposure.
• Isotonic / osmolality. Isotonic describes a solution whose solute concentration matches that of the reference fluid it will contact, avoiding osmotic stress in a cell-based assay. Osmolality is the measurement, osmoles of solute per kilogram of solvent, used to check whether a prepared solution meets that target.
• Stock solution / serial dilution. A stock solution is a single, relatively concentrated reconstituted batch kept as the source for further dilutions. A serial dilution is a stepwise series of dilutions from that stock, each step diluting the previous one by a fixed factor, used to generate a concentration range for a dose-response experiment.
• Cryoprotectant. An additive included in some formulations to limit ice-crystal damage during freezing. Not every peptide formulation includes one, which is one more reason two vials of the same peptide from different manufacturers are not automatically equivalent.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, ~pH 6) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Accessoriesaccessories

Bacteriostatic water and research supplies

Testing and Quality

• Certificate of Analysis (CoA). A batch-specific lab document reporting identity (usually by mass spectrometry) and purity (usually by HPLC) for that particular lot, often alongside water content, counterion content, residual solvents and endotoxin results. Browse ours at /coa.
• HPLC (high-performance liquid chromatography). A lab technique that separates the components of a sample and reports each as a percentage of the total peak area. This is the source of the purity figure discussed above.
• Purity (peak-area purity). Shorthand for the HPLC result. See the callout above for why this number is not the same as peptide content by weight.
• Mass spectrometry (MS). Confirms a peptide's identity by measuring the mass-to-charge ratio of ionized molecules and comparing the observed mass against the theoretical mass calculated from the amino acid sequence.
• Endotoxin. A component of the outer membrane of Gram-negative bacteria (lipopolysaccharide) that can trigger a strong immune response even after the bacteria themselves are gone.
• Endotoxin Unit (EU). The standardized potency unit endotoxin results are reported in. A CoA showing less than 1 EU/mg is a low endotoxin burden for typical in-vitro or in-vivo research use, while immune-cell or cytokine assays commonly call for a stricter threshold, often cited as less than 0.1 EU/mg.
• LAL assay (Limulus Amebocyte Lysate). The standard laboratory method for measuring endotoxin content, using a reagent derived from horseshoe crab blood cells that reacts detectably in the presence of endotoxin.
• USP General Chapter 85. The United States Pharmacopeia's compendial bacterial endotoxins test chapter, with equivalents in the European and Japanese pharmacopeias. When a CoA cites it, that names the testing standard being used, not a claim about the finished product's regulatory status.
• TFA salt (trifluoroacetate). The default counterion left behind by standard Fmoc solid-phase peptide synthesis, where trifluoroacetic acid is used to cleave the finished peptide from its resin and strip protecting groups.
• Acetate salt. Produced by exchanging the TFA counterion for acetate, typically through repeated dissolution in dilute acetic acid followed by re-lyophilization. Acetate is a lighter ion than TFA, so more of a given milligram is peptide rather than counterion, and it avoids some assay-interference concerns associated with residual TFA.
• Counterion. The charged ion that balances a peptide's own charge in salt form, TFA and acetate being the two common examples above. It adds measurable weight to the powder without being part of the peptide itself.
• Isoelectric point (pI). The pH at which a peptide carries no net electrical charge. It affects solubility and is one reason some peptides dissolve more readily in an acidic diluent, such as acetic acid water, than in plain water.
• Third-party lab testing. Analysis performed by an independent laboratory rather than the manufacturer or seller itself. Our batches are tested by Janoshik or Liquilabs, both independent of PeptidesDirect, with results published per-batch at /coa.
• Research Use Only (RUO). A labeling category, originally defined by the FDA for in-vitro diagnostic products, meaning material intended for laboratory research rather than diagnosis, treatment or human consumption. RUO status describes the product's actual intended use, and RUO material has not gone through the safety, purity and efficacy review that applies to an approved pharmaceutical.
• GMP (Good Manufacturing Practice). A specific, audited regulatory manufacturing framework requiring validated processes, environmental monitoring, batch records and stability testing. Research-grade peptides are typically HPLC and MS tested but not manufactured or inspected under a GMP-certified system, so a GMP-grade claim on a research peptide is worth verifying against an actual certificate rather than taking at face value.
• Oxidation (degradation pathway). Affects methionine, tryptophan and cysteine residues in particular, where exposure to air or light adds oxygen to the side chain and can change the peptide's activity.
• Deamidation (degradation pathway). Converts asparagine or glutamine residues into a different amino acid, often accelerated at asparagine-glycine or glutamine-glycine motifs in the sequence.
• Hydrolysis (degradation pathway). Breakdown of the peptide backbone itself through reaction with water, more likely the longer a peptide sits reconstituted in solution rather than in lyophilized form.
• Racemization (degradation pathway). Conversion of an amino acid from its natural configuration to its mirror-image form, which can alter or eliminate biological activity at that position.
• Aggregation (degradation pathway). Peptide molecules clumping together into larger complexes, sometimes visible as cloudiness or particulate in a reconstituted solution, generally treated as a sign the material should not be used further.

Pharmacology

• Peptide. A chain of roughly 2 to 50 amino acids joined by peptide bonds. The cutoff against protein is conventional, not a hard scientific rule.
• Protein. Generally a chain of 50 or more amino acids, often folding into a stable three-dimensional or multi-chain structure. The boundary with peptide is conventional rather than absolute.
• Amino acid. The building-block molecule of a peptide or protein, each with a common backbone and a distinct side chain that gives it its individual chemical properties.
• Sequence. The ordered list of amino acids making up a peptide, conventionally written from the N-terminus to the C-terminus, left to right.
• N-terminus. The end of a peptide chain with a free amino group. By convention it is written first in a sequence.
• C-terminus. The end of a peptide chain with a free carboxyl group. By convention it is written last in a sequence.
• Peptide bond. The covalent amide bond linking the carboxyl group of one amino acid to the amino group of the next, formed with the loss of a water molecule.
• Disulfide bond. A covalent sulfur-sulfur linkage formed between two cysteine residues, either within a single chain, folding it into a ring or loop, or between two separate chains. It is a structural feature of some cyclic peptides.
• Agonist. A molecule that binds a receptor and activates it, producing a biological response.
• Antagonist. A molecule that binds a receptor without activating it, blocking an agonist from producing its usual effect at that site.
• Receptor / GPCR. A protein, often embedded in a cell's outer membrane, that a signaling molecule binds to trigger a response inside the cell. A G-protein-coupled receptor (GPCR) is the largest receptor family and includes the melanocortin and incretin receptor families described in the next section.
• EC50. The concentration of an agonist that produces half of its maximum possible stimulatory effect in an assay. A lower EC50 generally indicates a more potent agonist at that receptor.
• IC50. The concentration of a compound that produces 50% inhibition in an assay, commonly used to describe antagonist potency or competitive binding.
• Half-life. The time it takes for a substance's concentration in a system, most often blood plasma in pharmacokinetic studies, to fall by half. It is a property of the specific molecule, route and species being measured, not a universal constant for peptides as a category.
• Bioavailability. The fraction of an administered dose that reaches systemic circulation in an active form. It depends heavily on the route studied, since a molecule that is stable by one route may be broken down before it ever reaches circulation by another.
• Subcutaneous. The tissue layer beneath the skin and above the muscle. A common study route for peptide administration in pharmacokinetic research.
• Intraperitoneal. The cavity surrounding the abdominal organs. A common injection route in rodent studies because it allows a relatively large volume and rapid absorption compared with some other routes.
• In vitro. Research conducted outside a living organism, for example in cell culture or a test tube.
• In vivo. Research conducted within a living organism, for example in an animal model.
• First-pass metabolism. The reduction in an administered substance's concentration before it reaches systemic circulation, typically due to metabolism in the gut wall or liver. A major reason most peptides are studied by injection routes rather than oral administration.
• DPP-4 (dipeptidyl peptidase-4). An enzyme that rapidly breaks down native GLP-1 near its N-terminus in circulation, which is why native GLP-1's own half-life is measured in minutes and why GLP-1-receptor-agonist research compounds typically carry amino-acid substitutions or other modifications designed to resist DPP-4 cleavage.

Peptide Classes

• Incretin. A hormone released from the gut after eating that stimulates insulin secretion and slows gastric emptying. GLP-1 and GIP are the two primary incretins studied in metabolic peptide research.
• GLP-1 (glucagon-like peptide-1). An incretin hormone and the namesake of the GLP-1 receptor agonist research class. Native GLP-1 is rapidly degraded by DPP-4, which is why research analogs in this class are built to resist that cleavage.
• GIP (glucose-dependent insulinotropic polypeptide). The second major incretin hormone, and the second receptor target in dual and triple agonist research compounds alongside GLP-1.
• Glucagon receptor. The receptor for glucagon, a hormone that raises blood glucose. Some newer multi-agonist research peptides target this receptor alongside the GLP-1 and GIP receptors as a third mechanism.
• Secretagogue. Broadly, any substance that triggers secretion of another substance from a cell. In peptide research the term is most often applied to growth-hormone secretagogues, compounds studied for stimulating pituitary release of growth hormone via the ghrelin receptor (GHS-R1a).
• GLP-1 receptor agonist (class). Research compounds designed to activate the GLP-1 receptor. Distinguishing structural features across the class typically include amino-acid substitutions for DPP-4 resistance and, in longer-acting members, a fatty-acid chain for albumin binding, as in the single-target research compound semaglutide.
• Dual and triple agonist. A research compound designed to activate more than one receptor at once, most often combinations of the GLP-1, GIP and glucagon receptors described above. Tirzepatide is studied as a dual GLP-1/GIP agonist, and retatrutide is studied as a triple agonist across all three of those receptors.
• GHRH analog. A research compound modeled on growth-hormone-releasing hormone (GHRH), the hypothalamic signal that prompts pituitary growth hormone release. Some GHRH analogs, such as CJC-1295, are modified to bind albumin and extend circulating half-life well beyond that of the natural hormone, while others, such as sermorelin and tesamorelin, stay closer to the native GHRH sequence or use a different stabilizing modification.
• GH secretagogue / ghrelin receptor agonist. A research compound studied for stimulating growth-hormone release by activating the ghrelin receptor (GHS-R1a) rather than the GHRH receptor pathway above. Different compounds in this class vary in how selectively they affect growth hormone release relative to other pituitary hormones. Ipamorelin is a widely studied example noted for relatively selective GH release with comparatively less impact on cortisol and prolactin than some older compounds in this class.
• Melanocortin receptor family. A family of five G-protein-coupled receptor subtypes (MC1R through MC5R) involved in processes ranging from pigmentation to appetite regulation to sexual desire. Different research peptides in this space are studied for different selectivity profiles across the five subtypes. Melanotan-2 is a non-selective research compound studied across several of those subtypes at once, in contrast to more receptor-specific candidates in the same family.
• Cyclic peptide vs. linear peptide. A linear peptide has a free N-terminus and C-terminus. A cyclic peptide's structure is closed into a ring, often through a disulfide bond between two cysteine residues, which can change its receptor selectivity and its resistance to enzymatic breakdown compared with a linear version.
• Chain-length naming (tripeptide, pentapeptide, pentadecapeptide). Peptides are often described by the number of amino acids they contain, using standard prefixes: tripeptide (3 residues, the copper-binding research compound GHK-Cu is a common example), pentapeptide (5), pentadecapeptide (15, the term used for BPC-157), and so on. The prefix is a structural description, not a brand or class name.
• TB-500 / thymosin beta-4 naming. TB-500 is a commercial name used inconsistently across the research-peptide market: some vendors apply it to the full 43-amino-acid thymosin beta-4 sequence, others to a shorter 7-amino-acid active fragment. The TB-500 listed here is the full-length 43-amino-acid sequence, identity-confirmed by mass spectrometry on its CoA, which is why checking a specific vendor's CoA rather than assuming from the name alone matters for this particular compound.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

CJC-1295 (No DAC)growth

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH(1-29) analog for GH/IGF-1 research. Research-grade lyophilized powder, specified purity >=99% (HPLC). Laboratory use only.

Sermorelingrowth

GHRH(1-29) analog for physiological growth hormone stimulation research

Tesamorelingrowth

Modified GHRH analog for lipodystrophy and metabolic liver research

Ipamorelingrowth

Highly selective growth hormone releaser that triggers natural GH pulses without raising cortisol or prolactin. Clean GH stimulation with minimal side effects - the most targeted growth hormone peptide available.

Melanotan-2growth

Tanning peptide that activates melanin production in the skin. Stimulates melanocyte receptors for natural UV-free pigmentation. Also researched for appetite regulation and libido effects.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

TB-500regeneration

Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.

Units and Measurement

• IU (International Unit). A measure of a substance's biological potency, calibrated against a WHO international reference standard rather than a fixed mass. IU-to-mg conversion factors are therefore substance-specific and cannot be assumed to carry over from one compound to another.
• mcg vs. mg. Microgram (mcg or µg) and milligram (mg) are both mass units. 1 mg equals 1,000 mcg, and misreading one for the other in a calculation is a straightforward but consequential order-of-magnitude error.
• U-100 syringe. A syringe marked in unit graduations where 100 unit-marks equal 1 mL, meaning each unit mark is a fixed volume of 0.01 mL. Those unit marks are a volume measurement, not the IU potency unit described above, and the two are easy to conflate.
• Molar concentration (M, mM). Molarity (M) is moles of solute per liter of solution. Millimolar (mM) is millimoles per liter, not per milliliter, a distinction that produces a thousand-fold error if missed.
• kDa / Da (kilodalton / dalton). The dalton is a unit of molecular mass. A kilodalton is 1,000 daltons, and peptide or protein molecular weights are commonly reported in this unit on a CoA or spec sheet, with most research peptides falling well under 5 kDa and larger proteins running into tens or hundreds of kDa.

Two tools on this site turn several of the definitions above into a direct calculation rather than manual arithmetic: the reconstitution calculator converts a target concentration and diluent volume into a draw volume, and the unit converter handles mcg-to-mg and related conversions.

Frequently Asked Questions

This glossary is provided for general research-education purposes and does not constitute dosing, medical, or legal advice. All peptides and reagents referenced are sold exclusively as laboratory research material and are not intended for human or veterinary use.